IP Library Granted Patent US 9,950,112
Granted Patent B2
US 9,950,112 · App. 13/817,165 · Granted Apr 24, 2018

Intelligent drug and/or fluid delivery system to optimizing medical treatment or therapy using pharmacodynamic and/or pharamacokinetic data

Inventors: Richard J. Melker (Gainesville, FL); Donn M. Dennis (Gainesville, FL); Jeremy Melker (Gainesville, FL); Mark Rice (Jacksonville, FL); Robert Hurley (Gainesville, FL)
Assignees: University of Florida Research Foundation, Incorporated; Xhale, Inc.
A61M5/1723A61M5/142A61M5/168A61M5/16854A61M5/172A61M5/31511G06Q50/22G06F19/3468
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,950,112
App. No.
13/817,165
Granted
Apr 24, 2018
Kind
B2
Abstract

A pharmacodynamic (PD), pharmacokinetic (PK), or both and PK guided infusion device, system and method optimizes the safety and efficacy of various forms of treatment or therapy (e.g., drug and/or fluid) in a variety of health-care and other settings.

Claims (21)

1. A medication delivery control system comprising:

(a) an apparatus comprising at least one photoplethysmography (PPG) sensor that obtains a PPG signal from a site at a subject's nose;

(b) an infusion device that provides medication to the subject's nose;

(c) a controller for receiving PPG signals from the PPG sensor and, based on the signals, increasing, decreasing or maintaining a rate of infusion of the infusion device, and

(d) an accelerometer or other motion sensing device

wherein the system is in a sleep mode wherein power consumption is reduced until the controller determines that the subject is sleeping or in state of respiratory depression based on signals from the accelerometer or other motion sensing device; and

wherein the medication delivery control system is a wearable device adapted to be secured to the nose and/or head of the subject.

2. The medication delivery control system according to claim 1 , wherein the PPG signals are obtained from the subject's nasal alar.

3. The medication delivery control system according to claim 1 , further comprising a nasal pressure or flow sensor, and optionally, an ECG electrode.

4. The medication delivery control system according to claim 1 , further comprising an intranasal tube that is adapted to be emplaced inside the subject's nostril and delivers pre-metered doses of medications.

5. The medication delivery control system according to claim 4 , wherein the system delivers nitric oxide, histamine, or methacholine to nasal mucosa, either as part of the medications or as a separate feed.

6. The medication delivery control system of claim 4 , wherein the medications comprise at least one of opioids, opioid antagonists, vasoactive drugs, steroids, dissociative agents and anxiolytics.

7. The medication delivery control system of claim 4 , wherein the system delivers medications through the nasal epithelium.

8. The medication delivery control system of claim 1 , further comprising at least one PPG sensor adapted to be secured to a peripheral site of the subject.

9. The medication delivery control system of claim 1 , wherein the system:

(i) obtains measurements of at least one of the subject's vital signs selected from the group consisting of nasal pressure/flow, electrocardiographic signals, blood pressure, heart rate, heart rate variability, arrhythmias, respiratory rate, respiratory effort indicative of work of breathing, inspiratory and expiratory breathing ratios (I:E ratios), patterns of indicative of normal respiration or respiratory depression, plethysmography signals, blood oxygen saturation, blood volume, including local arterial blood flow amplitude, venous capacitance and comparative flows and capacitance from two or more site indicative of hypovolemia/shock and/or loss of extremity perfusion, pulse transit time, pulse wave velocity and combinations thereof,

(ii) processes the measurements to determine a relative state of health and, based on the determination,

(iii) infuses at least one medication to the subject based on the determination in (ii).

10. The medication delivery control system of claim 1 , wherein the system is operated by remote personnel.

11. The medication delivery control system of claim 1 , wherein the system is part of a helmet, telemetry or communications gear.

12. The medication delivery control system of claim 9 , wherein the system wirelessly communicates vital sign information to remote personnel.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2018
From: XHALE, INC.
To: XHALE ASSURANCE, INC.
Reel/Frame 047471/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2013
From: MELKER, JEREMY
To: XHALE, INC.
Reel/Frame 030401/0024 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2013
From: MELKER, JEREMY
To: XHALE, INC.
Reel/Frame 030304/0727 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2013
From: MELKER, RICHARD J.; DENNIS, DONN M.; RICE, MARK; HURLEY, ROBERT; GOLD, MARK S.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 030304/0984 →
Continuity (2)
Provisional Application 61374583 · Aug 17, 2010
Related Publication 20130296823A1 · Nov 7, 2013